Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 21, 2005; 11(47): 7457-7460
Published online Dec 21, 2005. doi: 10.3748/wjg.v11.i47.7457
Published online Dec 21, 2005. doi: 10.3748/wjg.v11.i47.7457
Time | Stomach | Small intestine | Cecum | Colon | |||||||||
(h) | Prodrug | 5-ASA | AC-5-ASA | Prodrug | 5-ASA | AC-5-ASA | Prodrug | 5-ASA | AC-5-ASA | Prodrug | 5-ASA | AC-5-ASA | |
4 | 19.8±4.8 | 0.0±0.0 | 0.0±0.0 | 41.6±30.8 | 0.0±0.0 | 0.0±0.0 | 7.7±7.6 | 14.7±17.3 | 7.3±12.6 | 6.3±11.0 | 0.8±1.0 | 1.8±1.6 | |
8 | 2.8±4.3 | 0.0±0.0 | 0.0±0.0 | 14.3±6.5 | 0.7±0.4 | 0.0±0.0 | 11.3±14.0 | 20.2±22.4 | 6.1±5.8 | 7.2±9.9 | 9.1±7.7 | 18.4±13.6 | |
12 | 0.0±0.0 | 0.1±0.1 | 0.4±0.5 | 1.7±0.4 | 0.5±0.7 | 2.5±3.9 | 9.4±11.8 | 4.7±7.4 | 6.2±6.4 | 17.2±24.0 | 17.3±23.7 | 16.6±17.9 | |
24 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 22.8±24.2 | 9.2±9.0 | 0.3±0.5 | 7.9±13.6 | 13.3±15.6 | 1.4±1.1 | 23.4±15.6 | |
Plasma | Urine | Feces | Liver | Total | |||||||||
Prodrug | 5-ASA | AC-5-ASA | Prodrug | 5-ASA | AC-5-ASA | Prodrug | 5-ASA | AC-5-ASA | Prodrug | 5-ASA | AC-5-ASA | recovery | |
4 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 69.3±29.0 |
8 | 0.0±0.0 | 0.5±0.3 | 4.0±2.6 | 0.0±0.0 | 0.2±0.1 | 2.0±1.3 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.3±0.1 | 3.0±2.2 | 65.0±11.9 |
12 | 0.0±0.0 | 0.4±0.5 | 4.7±4.0 | 0.0±0.0 | 0.3±0.4 | 2.8±2.4 | 0.3±0.5 | 7.1±8.2 | 7.1±8.0 | 0.0±0.0 | 0.2±0.3 | 0.4±0.8 | 50.5±20.0 |
24 | 0.0±0.0 | 1.4±1.2 | 1.9±1.9 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 4.3±7.4 | 1.3±1.3 | 9.3±11.8 | 0.0±0.0 | 1.4±1.3 | 2.1±2.5 | 12.6±7.6 |
- Citation: Zou MJ, Cheng G, Okamoto H, Hao XH, An F, Cui FD, Danjo K. Colon-specific drug delivery systems based on cyclodextrin prodrugs: In vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates. World J Gastroenterol 2005; 11(47): 7457-7460
- URL: https://www.wjgnet.com/1007-9327/full/v11/i47/7457.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i47.7457